Literature DB >> 29027568

[Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

S Petersenn1, M Christ-Crain2, M Droste3, R Finke4, J Flitsch5, I Kreitschmann-Andermahr6, A Luger7, J Schopohl8, G Stalla9.   

Abstract

Acromegaly is a rare and severe condition, presenting with typical signs and symptoms. The diagnosis is often initially made years after the first manifestations of the disease. In more than 99% of patients the disease is caused by a benign pituitary tumor that secretes growth hormone (GH). The diagnosis is based on the presence of increased insulin-like growth factor 1 (IGF-1) levels and a lack of GH suppression in the oral glucose tolerance test. The standard imaging procedure for tumor detection is magnetic resonance imaging in the region of the sella turcica. Treatment includes surgical, drug and radiation therapy. Important factors are an intensive aftercare of the patient, controls for detection of tumor recurrence and pituitary insufficiency as well as assessment of various organ functions and risk constellations. Patient care should involve close cooperation between endocrinologists, neurosurgeons and general practitioners as well as other specialist disciplines.

Entities:  

Keywords:  Cardiovascular diseases; Endocrine system diseases; Insulin-like growth factor I; Pituitary adenoma; Sleep apnea syndromes

Mesh:

Substances:

Year:  2017        PMID: 29027568     DOI: 10.1007/s00108-017-0331-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  43 in total

1.  Goiter, cardiovascular and metabolic disorders in patients with acromegaly.

Authors:  F Golkowski; A Krzentowska-Korek; A Baldys-Waligorska; A Hubalewska-Dydejczyk
Journal:  Endocr Regul       Date:  2011-10

2.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

Authors:  Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

Review 3.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

4.  Clinical characteristics of pain in patients with pituitary adenomas.

Authors:  C Dimopoulou; A P Athanasoulia; E Hanisch; S Held; T Sprenger; T R Toelle; J Roemmler-Zehrer; J Schopohl; G K Stalla; C Sievers
Journal:  Eur J Endocrinol       Date:  2014-08-12       Impact factor: 6.664

Review 5.  Acromegaly and bone disease.

Authors:  Jeremy R Anthony; Adriana G Ioachimescu
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-12       Impact factor: 3.243

6.  Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up.

Authors:  B L Herrmann; H Baumann; O E Janssen; R Görges; K W Schmid; K Mann
Journal:  Exp Clin Endocrinol Diabetes       Date:  2004-05       Impact factor: 2.949

7.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

Review 8.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

9.  Effects of medical therapies for acromegaly on glucose metabolism.

Authors:  C Urbani; C Sardella; A Calevro; G Rossi; I Scattina; M Lombardi; I Lupi; L Manetti; E Martino; F Bogazzi
Journal:  Eur J Endocrinol       Date:  2013-06-07       Impact factor: 6.664

Review 10.  Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review.

Authors:  Kosma Wolinski; Agata Czarnywojtek; Marek Ruchala
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.